Icandra is a diabetes medicine that is used together with diet and exercise to control the blood glucose (sugar) in adults with type 2 diabetes. It is used: - in patients whose blood glucose is insufficiently controlled with metformin taken alone; - in patients who are already taking the combination of vildagliptin and metformin as separate tablets; - together with other diabetes medicines, including insulin, when these medicines do not provide adequate control of the blood glucose. Icandra contains the active substances vildagliptin and metformin hydrochloride. This medicine is the same as Eucreas, which is already authorised in the EU. The company that makes Eucreas has agreed that its scientific data can be used for Icandra (informed consent).
Therapeutic Indication
### Therapeutic indication Icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: - in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).
Therapeutic Area (MeSH)
N/AATC Code
A10BD08
ATC Item
metformin and vildagliptin
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
EMA Name
Icandra (previously Vildagliptin / metformin hydrochloride Novartis)
Medicine Name
Icandra (previously Vildagliptin / metformin hydrochloride Novartis)
Aliases
N/ANo risk management plan link.
